Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs
Authors:
- 15 December 2015
- journal article
- viewpoint
- Published by American Medical Association (AMA) in JAMA
- Vol. 314 (23) , 2503-3
Abstract
Opinion from JAMA — Payer and Policy Maker Steps to Support Value-Based Pricing for DrugsKeywords
This publication has 4 references indexed in Scilit:
- National Health Expenditure Projections, 2014–24: Spending Growth Faster Than Recent TrendsHealth Affairs, 2015
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)Annals of Oncology, 2015
- ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance MeasuresCirculation, 2014
- Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2014